By Professor Monica M. Lahra

Journal articles

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Australian Gonococcal Surveillance Programme 1 October to 31 December 2020', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.44

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2021', Communicable Diseases Intelligence 2018, 45

Lahra MM; George CRR; Shoushtari M; Hogan TR, 2021, 'Australian Meningococcal Surveillance Programme Annual Report, 2020', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.46

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Communicable Diseases Intelligence', COMMUNICABLE DISEASES INTELLIGENCE, 45, http://dx.doi.org/10.33321/cdi.2021.45.47

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2021', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.45

Lahra MM; Shoushtari M; Hogan TR, 2021, 'Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2020', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.36

Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR, 2021, 'Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18', Journal of Antimicrobial Chemotherapy, 76, pp. 1815 - 1821, http://dx.doi.org/10.1093/jac/dkab099

Lahra MM; Hogan TR; Shoushtari M; Armstrong BH, 2021, 'Australian Gonococcal Surveillance Programme Annual Report, 2020', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.24

Lahra MM; Hogan TR; Shoushtari M; Armstrong BH, 2021, 'Australian Gonococcal Surveillance Programme Annual Report, 2020.', Communicable Diseases Intelligence, 45, http://dx.doi.org/10.33321/cdi.2021.45.24

Armstrong BH; Limnios A; Lewis DA; Hogan T; Kundu R; Ray S; Shoushtari M; El Nasser J; Driscoll T; Lahra MM, 2021, 'Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales?', COMMUNICABLE DISEASES INTELLIGENCE, 45, http://dx.doi.org/10.33321/10.33321/cdi.2021.45.12

Armstrong BH; Limnios A; Lewis DA; Hogan T; Kundu R; Ray S; Shoushtari M; El Nasser J; Driscoll T; Lahra MM, 2021, 'Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales?', Communicable Diseases Intelligence 2018, 45, http://dx.doi.org/10.33321/cdi.2021.45.12

Trembizki E; Jennison AV; Buckley C; Bright A; Holds J; Ward A; Pitt J; Pendle S; Baird R; Freeman K; Robson J; Mhango L; Lowry K; Lahra M; Whiley D, 2021, 'Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia', Journal of Antimicrobial Chemotherapy, 76, pp. 270 - 271, http://dx.doi.org/10.1093/JAC/DKAA402

Lahra MM; Shoushtari M; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.96

Lahra MM; Shoushtari M; Hogan TR, 2020, 'Meningococcal Surveillance Australia Reporting period 1 July to 30 September 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.95

Hong S; Putsathit P; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR, 2020, 'Laboratory-based surveillance of clostridium difficile infection in australian health care and community settings, 2013 to 2018', Journal of Clinical Microbiology, 58, http://dx.doi.org/10.1128/JCM.01552-20

Cabrera-Aguas M; Khoo P; Lahra MM; Watson SL, 2020, 'Travel associated microbial keratitis: is resistance a risk?', Travel Medicine and Infectious Disease, 38, http://dx.doi.org/10.1016/j.tmaid.2020.101903

Watson SL; Gatus BJ; Cabrera-Aguas M; Armstrong BH; George CR; Khoo P; Lahra MM, 2020, 'Bacterial Ocular Surveillance System (BOSS) Sydney, Australia 2017-2018', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.86

Lahra MM; Shoushtari M; Ray S, 2020, 'Meningococcal Surveillance Australia Reporting period 1 April to 30 June 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.81

Hepschke JL; Ung L; Cabrera-Aguas M; Ross C; Kumar N; Lahra MM; Watson S, 2020, 'Pediatric Microbial Keratitis: Experience From Tertiary Referral Centers in New South Wales, Australia', Pediatric Infectious Disease Journal, 39, pp. 883 - 888, http://dx.doi.org/10.1097/INF.0000000000002723

Lahra MM; Shoushtari M; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme: 1 April to 30 June 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.74

Lahra MM; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme: 1 July to 30 September 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.73

Ferreyra C; Osborn J; Moussy F; Alirol E; Lahra M; Whiley D; Shafer W; Unemo M; Klausner J; Cirino CK; Wi T, 2020, 'Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus', Plos One, 15, http://dx.doi.org/10.1371/journal.pone.0237424

Lahra MM; Hogan TR, 2020, 'Australian Meningococcal Surveillance Programme annual report, 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.62

Lahra MM; Shoushtari M; Hogan TR, 2020, 'Meningococcal Surveillance Australia Reporting period 1 January to 31 March 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.65

George CRR; Kundu RL; Whiley DM; Lahra MM, 2020, 'Are sex norms the norm in gonococcal surveillance?', Lancet Microbe, 1, pp. e143 - e144, http://dx.doi.org/10.1016/S2666-5247(20)30087-2

Khoo P; Cabrera-Aguas MP; Nguyen V; Lahra MM; Watson SL, 2020, 'Microbial keratitis in Sydney, Australia: risk factors, patient outcomes, and seasonal variation', Graefe S Archive for Clinical and Experimental Ophthalmology, 258, pp. 1745 - 1755, http://dx.doi.org/10.1007/s00417-020-04681-0

Lahra MM; Shoushtari M; George CRR; Armstrong BH; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme Annual Report, 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.58

Lahra MM; Shoushtari M; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme, 1 January to 31 March 2020', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.61

Lahra MM; Hogan TR, 2020, 'Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.47

Lahra MM; Hogan TR, 2020, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.50

Lahra MM; Hogan TR, 2020, 'Australian Gonococcal Surveillance Programme, 1 April to 30 June 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.37

Lahra MM; Enriquez RP; Hogan TP, 2020, 'Australian Meningococcal Surveillance Programme annual report, 2018', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.10

Cabrera-Aguas M; Khoo P; George CRR; Lahra MM; Watson SL, 2020, 'Antimicrobial resistance trends in bacterial keratitis over 5 years in Sydney, Australia', Clinical and Experimental Ophthalmology, 48, pp. 183 - 191, http://dx.doi.org/10.1111/ceo.13672

Fifer H; Hughes G; Whiley D; Lahra MM, 2020, 'Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia', Lancet Infectious Diseases, 20, pp. 276 - 278, http://dx.doi.org/10.1016/S1473-3099(20)30055-4

Lahra MM; Enriquez RP; George CRR, 2020, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2018', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.5

Lahra MM; Enriquez RP, 2020, 'Australian Gonococcal Surveillance Programme 1 January to 31 March 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.3

Lahra MM; Enriquez RP; George CRR, 2020, 'Australian Gonococcal Surveillance Programme Annual Report, 2018', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.4

Lahra MM; Enriquez RP, 2020, 'Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2019', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2020.44.9

Gilbey T; McIver C; Brandenburg U; Goeman E; Polkinghorne A; Lahra M; Branley J, 2020, 'Suspected materno-fetal transmission of neisseria meningitidis serogroup w clonal complex 11 causing early- onset neonatal sepsis', Open Forum Infectious Diseases, 7, http://dx.doi.org/10.1093/ofid/ofaa039

Lahra MM; Enriquez RP, 2020, 'Australian Gonococcal Surveillance Programme 1 April to 30 June 2017', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2019.44.7

Lahra MM; Enriquez RP, 2020, 'Australian Gonococcal Surveillance Programme 1 January to 31 March 2017', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2019.44.8

Lahra MM; Enriquez RP, 2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2017', Communicable Diseases Intelligence 2018, 44, http://dx.doi.org/10.33321/cdi.2019.44.6

Lahra MM; Enriquez RP, 2020, 'Australian Gonococcal Surveillance Programme 1 July to 30 September 2017.', Communicable Diseases Intelligence, 44, http://dx.doi.org/10.33321/cdi.2020.44.6

Badahdah AM; Bakarman MA; Khatami A; Tashani M; Barasheed O; Alfelali M; Azeem MI; Bokhary H; Soltan O; Lahra MM; Jeoffreys N; Kok J; Dwyer DE; Booy R; Rashid H, 2020, 'Meningococcal and pneumococcal carriage in Hajj pilgrims: Findings of a randomized controlled trial', Journal of Travel Medicine, 27, http://dx.doi.org/10.1093/JTM/TAAA032

Watson SL; Cabrera-Aguas M; Keay L; Khoo P; McCall D; Lahra MM, 2020, 'The clinical and microbiological features and outcomes of fungal keratitis over 9 years in Sydney, Australia', Mycoses, 63, pp. 43 - 51, http://dx.doi.org/10.1111/myc.13009

Lahra MM; Enriquez RP, 2019, 'Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2017.', Commun Dis Intell (2018), 43, http://dx.doi.org/10.33321/cdi.2019.43.62

Khoo P; Cabrera-Aguas M; Robaei D; Lahra MM; Watson S, 2019, 'Microbial Keratitis and Ocular Surface Disease: A 5-Year Study of the Microbiology, Risk Factors and Clinical Outcomes in Sydney, Australia', Current Eye Research, 44, pp. 1195 - 1202, http://dx.doi.org/10.1080/02713683.2019.1631852

Hanrahan JK; Hogan TR; Buckley C; Trembizki E; Mitchell H; Lau CL; Whiley DM; Lahra MM, 2019, 'Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history', Journal of Antimicrobial Chemotherapy, 74, pp. 2214 - 2219, http://dx.doi.org/10.1093/jac/dkz182

Roczo-Farkas S; Cowley D; Bines JE, 2019, 'Australian Rotavirus Surveillance Program: Annual Report, 2017', Communicable Diseases Intelligence, 43, http://dx.doi.org/10.33321/cdi.2019.43.28

Ebeyan S; Windsor M; Bordin A; Mhango L; Erskine S; Trembizki E; Mokany E; Tan LY; Whiley D; Cunningham P; Wand H; Donovan B; Kaldor J; Conway D; Ryder N; McNulty A; Templeton D; Guy R; Lahra M; Gunathilake M, 2019, 'Evaluation of the ResistancePlus GC (beta) assay: A commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae', Journal of Antimicrobial Chemotherapy, 74, pp. 1820 - 1824, http://dx.doi.org/10.1093/jac/dkz108

Back to profile page